| Autor: |
Merino D; Department of Child and Adolescent Psychiatry, Children's Hospitals of Nice, CHU-Lenval, 06200 Nice, France.; CoBTek Laboratory, Université Côte d'Azur, 06000 Nice, France.; Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France., Gérard AO; Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France., Destere A; Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France., Askenazy F; Department of Child and Adolescent Psychiatry, Children's Hospitals of Nice, CHU-Lenval, 06200 Nice, France.; CoBTek Laboratory, Université Côte d'Azur, 06000 Nice, France., Drici MD; Pharmacovigilance Center, Department of Pharmacology, University Hospital of Nice, 06000 Nice, France., Thümmler S; Department of Child and Adolescent Psychiatry, Children's Hospitals of Nice, CHU-Lenval, 06200 Nice, France.; CoBTek Laboratory, Université Côte d'Azur, 06000 Nice, France. |
| Abstrakt: |
Antipsychotic drugs (APs) aim to treat schizophrenia, bipolar mania, and behavioral symptoms. In child psychiatry, despite limited evidence regarding their efficacy and safety, APs are increasingly subject to off-label use. Studies investigating addictology-related symptoms in young people being scarce, we aimed to characterize the different patterns of AP misuse and withdrawal in children and adolescents relying on the WHO pharmacovigilance database (VigiBase ® , Uppsala Monitoring Centre, Sweden). Using the standardized MedDRA Query 'drug abuse, dependence and withdrawal', disproportionality for each AP was assessed with the reporting odds ratio and the information component. A signal was detected when the lower end of the 95% confidence interval of the information component was positive. Results revealed mainly withdrawal symptoms in infants (under 2 years), intentional misuse in children (2 to 11 years), and abuse in adolescents (12 to 17 years). Olanzapine, risperidone, aripiprazole, and quetiapine were disproportionately reported in all age groups, with quetiapine being subject to a specific abuse signal in adolescents. Thus, in adolescents, the evocation of possible recreational consumption may lead to addiction-appropriate care. Further, in young patients with a history of AP treatment, a careful anamnesis may allow one to identify misuse and its role in the case of new-onset symptoms. |
